Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds

被引:65
作者
Bruesewitz, Carsten [1 ]
Schendler, Andreas
Funke, Adrian
Wagner, Torsten
Lipp, Ralph
机构
[1] Schering AG, Pharmaceut Dev, D-13342 Berlin, Germany
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Free Univ Berlin, Inst Pharm, D-12169 Berlin, Germany
关键词
absorption enhancer; nanoemulsion; poloxamer;
D O I
10.1016/j.ijpharm.2006.08.022
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
On the basis of Pluronic (R) P104 as primary emulsifier and Lauroglycol (R) d90 as amphiphilic oil phase, two nanoemulsion systems were developed with Pluronic (R) L62 or L81 as secondary emulsifiers. The possible nanoemulsion region of combinations of these excipients was described in ternary phase diagrams. Three formulations were selected from the nanoemulsion region and their potential impact on oral absorption was examined in the Caco-2 monolayer model of the small intestine. The apparent pen-neability of the BCS class III compound Atenolol was enhanced 2.5-fold, of BCS class 11 compound Danazol 3.2-fold and of BCS class I compound Metoprolol 1.4-fold. The three formulations were very well tolerated by the Caco-2 cells, which was confirmed by TEER measurements, a MTT test and a LDH release test. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 24 条
[1]
ABRAHAMSSON B, 2003, DRUG BIOAVAILABILITY
[2]
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells [J].
Batrakova, EV ;
Li, S ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :845-854
[3]
Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers [J].
Batrakova, EV ;
Han, HY ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 1998, 15 (06) :850-855
[4]
Chen WQ, 2002, CELL CULTURE MODELS OF BIOLOGICAL BARRIERS, P143
[5]
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs [J].
Dressman, JB ;
Reppas, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S73-S80
[6]
Eccleston G. M., 2002, ENCY PHARM TECHNOLOG, V2, P1066
[7]
FLETCHER DI, 1988, STRUCTURE REACIVITY, P303
[8]
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery [J].
Kabanov, AV ;
Batrakova, EV ;
Alakhov, VY .
JOURNAL OF CONTROLLED RELEASE, 2002, 82 (2-3) :189-212
[9]
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification [J].
Kasim, Nehal A. ;
Whitehouse, Marc ;
Ramachandran, Chandrasekharan ;
Bermejo, Marival ;
Lennernas, Hans ;
Hussain, Ajaz S. ;
Junginger, Hans E. ;
Stavchansky, Salomon A. ;
Midha, Kamal K. ;
Shah, Vinod P. ;
Amidon, Gordon L. .
MOLECULAR PHARMACEUTICS, 2004, 1 (01) :85-96
[10]
KATAOKA K, 1993, J CONTROL RELEASE, V24, P119